- Home
- GERN
GERN
Geron Corporation
as 11-15-2024 4:00pm EST
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 2.5B | IPO Year: | 1996 |
| Target Price: | $6.95 | AVG Volume (30 days): | 9.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.64 - $5.34 | Next Earning Date: | 11-07-2024 |
| Revenue: | $29,480,000 | Revenue Growth: | 9199.68% |
| Revenue Growth (this year): | 30930.8% | Revenue Growth (next year): | 315.72% |
Latest Geron Corporation News
GERN Breaking Stock News: Dive into GERN Ticker-Specific Updates for Smart Investing
Business Wire
6 days ago
Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development
Business Wire
6 days ago
Geron to Participate in the Stifel 2024 Healthcare Conference
Simply Wall St.
7 days ago
Analysts Are Upgrading Geron Corporation (NASDAQ:GERN) After Its Latest Results
Simply Wall St.
8 days ago
Geron Third Quarter 2024 Earnings: Beats Expectations
GuruFocus.com
9 days ago
Geron Corp (GERN) Q3 2024 Earnings Call Highlights: Strong Rytelo Launch and Strategic ...
TipRanks
9 days ago
Geron Secures $250M Funding and Strong Q3 Sales
BioPharma Dive
9 days ago
Tezspire succeeds in chronic rhinosinusitis; Gilead writes down Trodelvy value
Motley Fool
10 days ago
Geron (GERN) Q3 2024 Earnings Call Transcript
Compare GERN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GERN Geron Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.